Trial Profile

A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rosomidnar (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors ProNAi Therapeutics; Sierra Oncology

Most Recent Events

09 Nov 2012 Results were presented at the the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, according to a ProNai Therapeutics media release.
09 Nov 2012 Status changed from recruiting to completed, as reported in a ProNAi Therapeutics media release.
04 Jun 2012 The ten planned dose cohorts have been completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com